Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

129 trials

NCT06742996
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Phase 3 · Argentina, Austria, Australia, Brazil, China, Germany, Spain, France, United Kingdom, Italy, Japan, South Korea, New Zealand, Poland, Puerto Rico, United States · 148 sites
Registry update: 29 Oct 2026
NCT06558604
Recruiting
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
Phase 2 · Belgium, France · 16 sites
Registry update: 10 Jul 2026
2023-506706-40-00
Recruiting
A phase II, multicenter, open-label study evaluating Glofitamab in combination with Venetoclax plus Zanubrutinib or Venetoclax alone in subjects with untreated or relapsed/refractory high-risk mantle-cell lymphoma
Phase 2/3 · Belgium, France · 16 sites
Registry update: 26 Jun 2026
NCT05990465
Recruiting
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Phase 1 · United States · 1 site
Registry update: 6 Aug 2026
NCT06788652
Recruiting
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Not applicable · United States · 1 site
Registry update: 24 Feb 2025
NCT06564038
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Phase 1/2 · Australia, China, Czechia, Germany, Denmark, Spain, France, United Kingdom, Italy, Japan, South Korea, Taiwan, United States · 59 sites
Registry update: 28 Oct 2026
2024-519790-19-00
Recruiting
IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED (GENETICALLY MODIFIED) THROUGH A LENTIVIRAL VECTOR TO EXPRESS A CHIMERIC RECEPTOR WITH ANTI-CD19 SPECIFICITY ASSOCIATED WITH CO-STIMULATORY SEQUENCES 4-1-BB AND CD3Ζ IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA.
Phase 1/2 · Spain · 2 sites
Registry update: 29 Sept 2025
NCT06697184
Recruiting
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Phase 1/2 · Australia, Brazil, China, Spain, France, United Kingdom, United States · 25 sites
Registry update: 26 Oct 2026
NCT06572618
Recruiting
Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
Phase 2 · United States · 2 sites
Registry update: 13 Mar 2026
NCT06208735
Recruiting
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · Canada · 7 sites
Registry update: 14 Oct 2026
NCT06852638
Recruiting
CD70-targeted immunoPET Imaging of Malignant Cancers
Phase 2 · China · 1 site
Registry update: 12 May 2026
NCT06054776
Recruiting
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 · United States · 1 site
Registry update: 3 Nov 2026
NCT06544265
Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 · United States · 5 sites
Registry update: 14 Apr 2026
NCT06542250
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Phase 1/2 · Australia, Canada, China, Germany, Denmark, Spain, France, Italy, Japan, United States · 30 sites
Registry update: 30 Sept 2026
NCT06553872
Recruiting
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Phase 2 · United States · 3 sites
Registry update: 23 Sept 2026
NCT06496308
Recruiting
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Phase 3 · China · 1 site
Registry update: 11 Jul 2024
NCT06464861
Recruiting
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
Phase 1 · China · 1 site
Registry update: 7 Feb 2025
NCT06252675
Recruiting
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 · United States · 4 sites
Registry update: 1 Oct 2026
NCT06224309
Recruiting
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Not applicable · Canada · 1 site
Registry update: 1 Oct 2026
NCT06363994
Recruiting
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Phase 3 · China, Czechia, Spain, France, Poland, Romania · 87 sites
Registry update: 27 Dec 2024

Ordered by registry start date. Freshness and sponsorship never change the order.